TCHP and melanoma: Verdinexor (KPT-335), a selective inhibitor of nuclear export, can effectively inhibit the proliferation and induce apoptosis in canine melanoma cells in vitro by restoring the function of tumor suppressor proteins and interfering with signaling pathways that promote cell growth [23].